Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 80
Filtrar
Mais filtros

Coleções SMS-SP
Intervalo de ano de publicação
1.
J Pediatr (Rio J) ; 83(5 Suppl): S209-16, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18000629

RESUMO

OBJECTIVE: To present relevant and updated information on the status of hypothyroidism in the pediatric population (newborn infants to adolescents). SOURCES: Original and review articles and books containing relevant updated data. SUMMARY OF THE FINDINGS: This review addressed data on the etiopathogeny of hypothyroidism and on the importance of screening for congenital hypothyroidism to assure early diagnosis and treatment of the newborn. We point out the difficulties experienced in the handling of subclinical hypothyroidism; we also address the importance of diagnosing autoimmune Hashimoto's thyroiditis, the high incidence of the disease among adolescents, mainly females, and the occurrence of a severe neurological condition, Hashimoto's encephalopathy. We indicate situations in which severe hypothyroidism may lead to puberty disorders (precocious or delayed puberty) and describe the importance of transcription factors in thyroid embryogenesis. Diagnostic and therapeutic criteria are also addressed. CONCLUSION: Thyroid hormones are necessary for normal growth and development since fetal life. Insufficient production or inadequate activity on the cellular or molecular level lead to hypothyroidism. These hormones are necessary for the development of the brain in the fetus and in the newborn infant. Neonatologists and pediatricians deal with child development issues in their practice, and many of these issues start during intrauterine life. Currently, with neonatal screening, neonatologists and pediatricians can prevent irreversible damage through early treatment. They should also be alert for dysfunctions such as subclinical hypothyroidism and Hashimoto's thyroiditis, which may provoke damage not only to growth, but also to the neurological and psychological development of these children and adolescents.


Assuntos
Hipotireoidismo/diagnóstico , Hipotireoidismo/terapia , Hormônios Tireóideos/fisiologia , Adolescente , Criança , Desenvolvimento Infantil/fisiologia , Pré-Escolar , Hipotireoidismo Congênito/diagnóstico , Feminino , Doença de Hashimoto/diagnóstico , Humanos , Hipotireoidismo/etiologia , Lactente , Recém-Nascido , Masculino , Triagem Neonatal , Hormônios Tireóideos/deficiência
2.
Arq Bras Endocrinol Metabol ; 51(1): 92-8, 2007 Feb.
Artigo em Português | MEDLINE | ID: mdl-17435861

RESUMO

AIM: The focus of this study was to evaluate the metabolic profile of Prader-Willi Syndrome (PWS) patients treated with growth hormone. PATIENTS AND METHODS: Seven patients (four boys and three girls) with ages between six years and six months and 14 years and 11 months were treated with GH 0.1 U/kg/day subcutaneous by six times a week, for two years. Anthropometric data, lipids, glucose, IGF-I and body composition were evaluated at baseline and after 12 and 24 months. RESULTS: IGF-I levels increased in all cases. Skin folds decreased. The mean reduction in body fat was 5.0% and the mean increased in lean mass was 7.6 kg in the prepubertal patients. The pubescent girl increased 4.8 kg and showed a 5.6% decrease in fat mass. A mean gain in the bone mass was 0.07 g/cm(2) (7.3%) in prepubescent cases, and 0.02 g/cm(2) (2.0%) in the pubescent girl. CONCLUSION: In our study GH treatment improved lean body and bone masses and had beneficial effect on lipid values.


Assuntos
Composição Corporal/efeitos dos fármacos , Hormônio do Crescimento Humano/uso terapêutico , Metabolismo dos Lipídeos/efeitos dos fármacos , Síndrome de Prader-Willi/metabolismo , Adipócitos/metabolismo , Tecido Adiposo/metabolismo , Adolescente , Composição Corporal/fisiologia , Índice de Massa Corporal , Criança , Feminino , Hormônio do Crescimento Humano/efeitos adversos , Humanos , Fator de Crescimento Insulin-Like I/metabolismo , Masculino , Síndrome de Prader-Willi/tratamento farmacológico , Dobras Cutâneas , Aumento de Peso/efeitos dos fármacos
3.
Diabetes Care ; 28(8): 1856-61, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16043723

RESUMO

OBJECTIVE: To look for technical simplification and economic efficiency in the treatment of pediatric diabetic ketoacidosis (DKA) with subcutaneous use of the fast-acting insulin analog (lispro) and compare its use with regular intravenous insulin treatment. RESEARCH DESIGN AND METHODS: In this controlled clinical trial from June 2001 to June 2003, we randomized 60 episodes of DKA with a blood glucose level > or = 16.6 mmol/l (300 mg/dl), venous pH <7.3 and/or bicarbonate <15 mmol/l, or ketonuria greater than + +. Of the 60 episodes, 30 were treated with subcutaneous lispro (0.15 units/kg) given every 2 h (lispro group) and the other 30 cases received continuous intravenous regular insulin (0.1 unit x kg(-1) x h(-1); CIRI group). Volume deficit was repaired with 10-ml/kg aliquots of 0.9% sodium chloride. Laboratory monitoring included hourly bedside capillary glucose, venous blood gas, beta-hydroxybutyrate, and electrolytes. Plasma blood glucose levels were measured on admission, 2 h after admission, when capillary blood glucose reached < or = 13.8 mmol/l (250 mg/dl), and 6, 12, and 24 h thereafter. RESULTS: Capillary glucose levels decreased by 2.9 and 2.6 mmol x l(-1) x h(-1) in the lispro and CIRI groups, respectively, but blood glucose fluctuated at different time intervals. In the CIRI group, metabolic acidosis and ketosis resolved in the first 6-h period after capillary glucose reached 13.8 mmol/l, whereas in the lispro group, they resolved in the next 6-h interval; however, both groups met DKA recovery criteria without complications. CONCLUSIONS: DKA treatment with a subcutaneous fast-acting insulin analog represents a cost-effective and technically simplified procedure that precludes intensive care unit admission.


Assuntos
Diabetes Mellitus Tipo 1/tratamento farmacológico , Insulina/análogos & derivados , Insulina/uso terapêutico , Glicemia/metabolismo , Criança , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/psicologia , Cetoacidose Diabética/prevenção & controle , Feminino , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/uso terapêutico , Injeções Subcutâneas , Insulina/administração & dosagem , Insulina/efeitos adversos , Insulina Lispro , Masculino , Cooperação do Paciente
4.
Rev Assoc Med Bras (1992) ; 62(6): 594-601, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27849238

RESUMO

The International Diabetes Federation (IDF-2015) estimates the existence of 30,900 children under 15 years old with type 1 diabetes mellitus (DM1) in Brazil, and an increase of 3.0% per year is expected. This review focused on meta-analysis and pediatric diabetes update articles in order to draw attention to the need of planning coping strategies to support this serious public health problem in coming years. DM1 is considered an immuno-mediated disease with a complex transmission influenced by genetic and environmental factors responsible for a gradual destruction of the insulin producing pancreatic beta cells. Seroconversion to DM1-associated autoantibodies and abnormalities in metabolic tests that assess insulin secretion and glucose tolerance can be used as predictive criteria of beta cells functional reserve and the onset of the clinical disease. Symptomatic DM1 treatment is complex and the maintenance of good metabolic control is still the only effective strategy for preserving beta cell function. Disease duration and hyperglycemia are both risk factors for the onset of chronic vascular complications that negatively affect the quality of life and survival of these patients. In this regard, health teams must be trained to provide the best possible information on pediatric diabetes, through continuing education programs focused on enabling these young people and their families to diabetes self-management.


Assuntos
Diabetes Mellitus Tipo 1/epidemiologia , Brasil/epidemiologia , Pré-Escolar , Diabetes Mellitus Tipo 1/fisiopatologia , Humanos , Fatores de Risco
5.
J Pediatr Endocrinol Metab ; 18(4): 347-53, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15844468

RESUMO

Adrenocortical carcinoma is a rare condition with an unpredictable prognosis as a rule. The authors retrospectively analyzed the clinical outcome of 46 patients (31 F, 15 M) during 16 years building up a numerical index for the prognosis, based on clinical and immunohistochemical data. Four indices were analyzed: J1= (Y + 2L + 4H)/T; J2 = (J1) square root of W/200; J3 = (O + Y + 2L + 4H)/T; J4 = (J3) square root W/200. Y = 1 when chronological age (CA) >33 mo, Y = 0 when CA < or =33 mo; L = 1 for right sided tumor and L = 0 for left sided tumor; H = 1 in presence of hypertension and H = 0 for normal blood pressure; T = length of disease in months; W = weight of tumor (g); O = 1 in the absence of p53 protein and O = 0 in the presence of p53. The chance of bad prognosis was observed when age is >33 mo, tumor is on the right side, systemic hypertension is present, tumor weight >250 g, in the absence of p53, J1, J2, J3 >0.4 (p <0.001) and J4 >0.5 (p <0.01). Clinical data and the mathematical model enabled us to establish probabilities of good prognosis in 78-96% and bad prognosis in 63-83%.


Assuntos
Neoplasias do Córtex Suprarrenal/fisiopatologia , Carcinoma Adrenocortical/fisiopatologia , Biomarcadores Tumorais/metabolismo , Modelos Biológicos , Adolescente , Neoplasias do Córtex Suprarrenal/metabolismo , Carcinoma Adrenocortical/metabolismo , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Prognóstico , Estudos Retrospectivos
6.
Arq Bras Endocrinol Metabol ; 49(1): 37-45, 2005 Feb.
Artigo em Português | MEDLINE | ID: mdl-16544033

RESUMO

It has become clear that a sexual brain dimorphism exists between males and females and animal studies have shown specific circuits developing depending on the sex. Since the first studies by Gorski, in rats, characterizing a sexually dimorphic nucleus in the pre optic area (SDN-POA) it has been accepted that the male sex imprint is done by estradiol, locally converted from testosterone through the action of a local aromatase. The presence of estradiol inhibits the apoptosis of the cells of SDN, making it bigger in the male sex. Other CNS regions have shown sexual dimorphism and we need a marker to allow us to identify these structures and, eventually, apply this information to clinical practice. In intersex patients, it may be of value to know which the brain sex of the patient is, since we have had many doubts in choosing the sex of rearing in many of these patients. It has not been uncommon that sexual inadequacies have occurred in some patients, causing a lot of discomfort and suffering for the patient himself as well as to his family. The progression of the knowledge in the field of brain sex may bring us another tool to deal with difficult cases of sex assignment in intersex patients.


Assuntos
Encéfalo/anatomia & histologia , Encéfalo/fisiologia , Animais , Feminino , Humanos , Masculino , Caracteres Sexuais
7.
Arq Bras Endocrinol Metabol ; 49(1): 71-8, 2005 Feb.
Artigo em Português | MEDLINE | ID: mdl-16544036

RESUMO

AIM: To show data on true hermaphrodites (TH) followed in two reference centers in the state of São Paulo. PATIENTS: Twenty-six TH patients have been followed from 1975 to 2004 in the Pediatric Endocrinology Unit, São Paulo University Medical School, and the other 10 patients from 1989 to 2004 in the GIEDDS-UNICAMP. METHODS: Clinical and pathological data were retrospectively analyzed, as well as the decision about the sex of rearing. RESULTS: Genital ambiguity was the most frequent complaint (34/36 cases) and the age at the first appointment was 20 mo (median). In 55.6% of the patients the female option was taken. The most frequent karyotype was 46,XX (47.2%), followed by mosaicisms (27.8%). SRY was negative in all 46,XX TH patients and the prevalent gonad was ovotestis (OT-47%), followed by ovary (OV-27%) and testis (TT-24%). The prevalent gonadal associations were OV+TT (30.5%), OT+OT (22.2%) and OT+OV (22.2%). The decision about the sex of rearing did not depend on karyotype, phallus size, and testosterone levels. However, the location of the urethral meatus was taken into account in this decision: 20 (80%) patients out of the 25 with perineal urethra were reared as females while all 11 with "non-perineal" urethra were reared as males. In five 46,XX patients reared as females it was possible to maintain the ovarian portion of the ovotestis. CONCLUSION: TH keeps on defying clinicians and investigators since most patients are 46,XX and SRY-negative, and yet they are able to develop testicular and ovarian tissues. The female sex of rearing seems to be the most adequate, and it is important to try to preserve, in these cases, the ovarian portion of the ovotestis, allowing the patient to have normal puberty and fertility.


Assuntos
Transtornos Ovotesticulares do Desenvolvimento Sexual , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Transtornos Ovotesticulares do Desenvolvimento Sexual/diagnóstico , Estudos Retrospectivos
8.
Arq Bras Endocrinol Metabol ; 49(1): 79-82, 2005 Feb.
Artigo em Português | MEDLINE | ID: mdl-16544037

RESUMO

We report on three patients with the clinical condition known as "XX male", which is uncommon in the pediatric age group. Patients have a male phenotype (usually without ambiguous genitalia) and testes; however, the karyotype is 46,XX. The diagnosis is usually made in adult life due to infertility; it may also be done by the pediatrician when there is ambiguous genitalia or gynecomastia. The SRY gene (Sex-determining Region of the Y chromosome) is detected in most cases, thus explaining the origin of testicular development; however, it is absent in 20% of the cases, thus indicating that gonadal determination is a complex process which depends on the interaction of many genes and transcription factors. The finding of only 3 cases in two reference services in a 30-year period indicates the rarity of this disorder among intersex cases.


Assuntos
Cromossomos Humanos X , Transtornos do Desenvolvimento Sexual , Adolescente , Transtornos do Desenvolvimento Sexual/diagnóstico , Transtornos do Desenvolvimento Sexual/genética , Humanos , Lactente , Cariotipagem , Masculino , Fenótipo
9.
Arq Bras Endocrinol Metabol ; 49(3): 384-9, 2005 Jun.
Artigo em Português | MEDLINE | ID: mdl-16543992

RESUMO

We studied the growth hormone receptor (GHR) gene in 6 patients with Laron syndrome (LS) from 4 unrelated families. Exons 2 to 10 were amplified by PCR using specific intronic pairs of primers. The PCR products were directly sequenced. Our results showed that all 6 patients carried a homozygous GAG>GAA mutation in codon 180 of exon 6. This mutation did not change the translated amino acid, but created an abnormal splice site deleting 8 amino acids from the extracellular domain of GHR. Members of all 4 kindreds with the E180splice mutation were genotyped for 4 polymorphic intragenic sites: The retention or exclusion of exon 3, single nucleotide polymorphisms present in exons 6 and 10, and intron 9 polymorphic site. All 6 patients presented the same haplotype. The E180splice mutation was first described in a population of Spanish descendants from the Andes of Southern Ecuador. This mutation was also found in oriental Jewish patients from Israel. Our families share the same intron-9 haplotype observed in Ecuadorian and Israeli patients. We conclude that the E180splice mutation is an important cause of LS in Brazil and there is probably a founder effect since our patients, Ecuadorian and Israeli patients share the same haplotype in intron 9.


Assuntos
Efeito Fundador , Hormônio do Crescimento Humano/deficiência , Síndrome de Laron/genética , Mutação/genética , Receptores da Somatotropina/genética , Adolescente , Adulto , Sequência de Aminoácidos , Sequência de Bases , Brasil , Criança , Pré-Escolar , Cristianismo , Equador , Éxons/genética , Feminino , Humanos , Israel , Judeus , Síndrome de Laron/diagnóstico , Masculino , Reação em Cadeia da Polimerase
10.
J Clin Endocrinol Metab ; 89(12): 5936-41, 2004 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-15579740

RESUMO

Familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT) are consequent to inactivating mutations of the calcium-sensing receptor (CaR) gene. FHH is usually associated with heterozygous inactivating mutations of the CaR gene, whereas NSHPT is usually due to homozygous inactivation of the CaR gene. FHH is generally asymptomatic and is characterized by mild to moderate lifelong hypercalcemia, relative hypocalciuria, and normal intact PTH, whereas individuals with NSHPT frequently show life-threatening hypercalcemia. In this study, we report a novel inactivating mutation of the CaR gene, identified in a 9-yr-old Brazilian girl who was found to be severely hypercalcemic during investigation of a 6-month history of headaches and vomits. Direct sequencing of the CaR gene from this patient showed a novel homozygous mutation (L13P) in exon 2. Functional characterization by intracellular calcium measurement by fluorometry showed that the mutant receptor had a dose-response curve shifted to the right relative to that of wild type. The proband's consanguineous parents, who had mild asymptomatic hypercalcemia, showed the same mutation in the heterozygous form. The mutation described in this study is the inactivating missense mutation present at the most N-terminal end among the known CaR missense mutations. This study reinforces the fact that patients with homozygous inactivation of the CaR gene may present with severe hypercalcemia in different phases of life.


Assuntos
Hipercalcemia/genética , Mutação de Sentido Incorreto , Receptores de Detecção de Cálcio/genética , Sequência de Bases , Brasil , Linhagem Celular , Criança , Consanguinidade , DNA/genética , Enzimas de Restrição do DNA , Éxons , Feminino , Heterozigoto , Homozigoto , Humanos , Hipercalcemia/sangue , Immunoblotting , Leucina , Prolina , Receptores de Detecção de Cálcio/metabolismo , Índice de Gravidade de Doença , Transfecção
11.
J Pediatr Endocrinol Metab ; 15(9): 1487-90, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12503855

RESUMO

We reviewed retrospectively seven children with congenital toxoplasmosis and precocious puberty. All seven showed very high levels of LH (25.2-155.0 IU/ml) and FSH (7.1-38.2) upon stimulation with GnRH. Three of them showed low GH response to an insulin tolerance test. All the children had severe mental retardation. We emphasize that children with congenital toxoplasmosis should have their hypothalamopituitary function evaluated even in subclinical situations that could be responsible for endocrinological disturbances such as precocious puberty.


Assuntos
Puberdade Precoce/etiologia , Toxoplasmose Congênita/complicações , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Hormônio Luteinizante/sangue , Masculino , Menarca , Estudos Retrospectivos , Toxoplasmose Congênita/fisiopatologia
12.
J Pediatr Endocrinol Metab ; 15(3): 331-3, 2002 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11926206

RESUMO

A 9 year-old boy with hypopituitarism and blood coagulation abnormalities is presented and discussed. The association between acquired von Willebrand disease and hypothyroidism has been reported but the combination of hypopituitarism and coagulopathy is unusual. Combined multiple clotting deficiencies are rare and, when present, factors V and VIII is the commonest association. Although it is known that hypothyroid patients may have a decrease in von Willebrand's factor (vWf) and factor VIII, there are no reports of hypopituitarism associated with combined deficiency of factors V, VIII, and vWf.


Assuntos
Deficiência do Fator V/complicações , Hemofilia A/complicações , Hipopituitarismo/complicações , Doenças de von Willebrand/complicações , Transtornos da Coagulação Sanguínea/sangue , Transtornos da Coagulação Sanguínea/complicações , Criança , Humanos , Hipopituitarismo/sangue , Hipopituitarismo/patologia , Imageamento por Ressonância Magnética , Masculino , Hipófise/patologia , Doenças de von Willebrand/sangue , Doenças de von Willebrand/patologia
13.
Arq Bras Endocrinol Metabol ; 48(5): 697-704, 2004 Oct.
Artigo em Português | MEDLINE | ID: mdl-15761541

RESUMO

We analyzed the clinical and molecular data of 205 patients with the three different clinical forms of 21-hydroxylase deficiency, in whom the clinical and molecular diagnosis were already defined. The most frequent mutations were I2 splice in the salt wasting form, I172N in the simple virilizing and V281L in the nonclassical form, presenting similar frequencies as those observed in other populations. We found a lower frequency of 21-hydroxylase gene deletion, similar to that previously identified in Argentinean and Mexican populations. Five new mutations were described in our population: G424S, H28+C, Ins 1003 1004 A, R408C and IVS2-2A>G. The genotype was classified in three groups according to the impairment of enzymatic activity observed in vitro, Group A: 0-2%, Group B: 3-7% and Group C: >20%. Group A mutations correlated with the salt wasting form, the Group B with simple virilizing form and Group C with the non classical form. The severity of genotype showed a positive correlation with higher 17OH-progesterone and testosterone levels. The I2 splice mutation in homo or hemizygosis confers classical form phenotype with both salt wasting and simple virilizing forms, precluding the prediction of the clinical form through genotype in pre and neonatal diagnosis. The good genotype-phenotype correlation in patients with 21-hydroxylase deficiency shows the usefulness of genotype to predict the clinical form for genetic counseling, prenatal diagnosis and to confirm neonatal screening diagnosis, except in cases with I2 splice mutation.


Assuntos
Hiperplasia Suprarrenal Congênita/genética , Criança , Feminino , Genótipo , Humanos , Masculino , Mutação , Fenótipo
14.
Horm Res Paediatr ; 78(2): 73-80, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22922775

RESUMO

BACKGROUND/AIMS: The purpose of this study was to compare adrenal gland reserve in acute lymphocytic leukemia (ALL) patients 8 weeks after treatment with either prednisone (PRED) or dexamethasone (DEX) during the induction phase of therapy. METHODS: A double-blind comparative study of patients treated with PRED and DEX was performed. Sixteen patients received PRED (40 mg/m(2)/day) and 13 patients received DEX (6 mg/m(2)/day), both for 28 days. A low-dose adrenocorticotropic hormone test (1.0 µg/m(2), IV) was performed before and weekly for 8 weeks after abrupt cessation of glucocorticoid therapy. Sixteen children without ALL were used as controls to determine the cutoff peak cortisol level (14.2 µg/dl). RESULTS: Both groups (PRED and DEX) displayed similar mean peak cortisol levels before treatment and during the 8 weeks of evaluation (p = 0.652). No relationship was observed between the incidence of infection/stress and peak cortisol level within each group, nor was there a difference in the frequency of infection/stress between groups (p = 0.359). Although the patients presented variations in peak cortisol during the study period, no signs or symptoms of adrenal insufficiency were observed. CONCLUSION: Patients who received PRED or DEX for 4 weeks showed similar adrenal reserves and infection rates for 8 weeks after abruptly stopping glucocorticoid therapy, suggesting that DEX, which is a better antileukemic drug than PRED, has similar adrenal suppression and recovery rates.


Assuntos
Glândulas Suprarrenais/metabolismo , Hormônio Adrenocorticotrópico/sangue , Antineoplásicos Hormonais/administração & dosagem , Dexametasona/administração & dosagem , Hidrocortisona/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Prednisolona/administração & dosagem , Adolescente , Antineoplásicos Hormonais/efeitos adversos , Criança , Pré-Escolar , Dexametasona/efeitos adversos , Método Duplo-Cego , Feminino , Humanos , Lactente , Masculino , Prednisolona/efeitos adversos
15.
Arq Bras Endocrinol Metabol ; 56(8): 496-500, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23295288

RESUMO

We report a case of adrenal hypoplasia congenita (AHC) and hypogonadotropic hypogonadism (HH) due to a novel DAX1 mutation. A 19-month-old boy with hyperpigmentation and failure to thrive came to our service for investigation. Three brothers of the patient had died due to adrenal failure, and a maternal cousin had adrenal insufficiency. Adrenoleukodystrophy was excluded. MRI showed normal pituitary and hypothalamus. Plasma hormone evaluation revealed high ACTH (up to 2,790 pg/mL), and low levels of androstenedione, DHEA-S, 11-deoxycortisol, and cortisol. At 14 years of age the patient was still prepubescent, his weight was 43.6 kg (SDS: -0.87) and his height was 161 cm (SDS: -0.36), with normal body proportions. In the GnRH test, basal and maximum values of LH and FSH were respectively 0.6/2.1 and < 1.0/< 1.0 U/L. Molecular investigation identified a novel mutation that consists of a deletion of codon 372 (AAC; asparagine) in exon 1 of DAX1. This mutation was not found in a study of 200 alleles from normal individuals. Prediction site analysis indicated that this alteration, located in the DAX1 ligand-binding domain, may damage DAX1 protein. We hypothesize that the novel (p.Asp372del) DAX1 mutation might be able to cause a disruption of DAX1 function, and is probably involved in the development of AHC and HH in this patient.


Assuntos
Hiperplasia Suprarrenal Congênita/genética , Receptor Nuclear Órfão DAX-1/genética , Doenças Genéticas Ligadas ao Cromossomo X/genética , Hipogonadismo/genética , Mutação/genética , Insuficiência Adrenal , Humanos , Hipoadrenocorticismo Familiar , Lactente , Masculino , Linhagem
16.
Arq Bras Endocrinol Metabol ; 55(1): 54-9, 2011 Feb.
Artigo em Português | MEDLINE | ID: mdl-21468520

RESUMO

OBJECTIVE: To report the genetic and metabolic profile of patients with Berardinelli-Seip syndrome (BSCL) followed at Instituto da Criança, HC-FMUSP. SUBJECTS AND METHODS: Patients with clinical features of BSCL (n = 5), all female, were evaluated through serum levels of glucose, insulin, lipids, leptin, and liver enzymes. Abdominal sonography and DNA analysis were also performed. RESULTS: Leptin deficiency and hypertriglyceridemia were found in all the patients. Three progressed to diabetes mellitus. Four patients have mutations in AGPAT2 gene and one have a mutation in CAV1 gene. CONCLUSION: The earliest metabolic abnormalities were hypertriglyceridemia and insulin resistance, culminating in the onset of diabetes at the time of puberty. Mutations in the AGPAT2 gene were the most frequent in our patients.


Assuntos
Lipodistrofia Generalizada Congênita/genética , Lipodistrofia Generalizada Congênita/metabolismo , 1-Acilglicerol-3-Fosfato O-Aciltransferase/genética , Adolescente , Caveolina 1/genética , Criança , Diabetes Mellitus/etiologia , Feminino , Humanos , Hipertrigliceridemia/diagnóstico , Hipertrigliceridemia/patologia , Leptina/sangue , Leptina/deficiência , Lipodistrofia Generalizada Congênita/complicações , Mutação/genética , Puberdade/fisiologia , Adulto Jovem
17.
Arq Bras Endocrinol Metabol ; 55(1): 60-6, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21468521

RESUMO

MCT8 is a cellular transporter of thyroid hormones important in their action and metabolization. We report a male patient with the novel inactivating mutation 630insG in the coding region in exon 1 of MCT8. He was characterized clinically by severe neurologic impairment (initially with global hypotonia, later evolving with generalized hypertonia), normal growth during infancy, reduced weight gain, and absence of typical signs and symptoms of hypothyroidism, while the laboratory evaluation disclosed elevated T3, low total and free T4, and mildly elevated TSH serum levels. Treatment with levothyroxine improved thyroid hormone profile but was not able to alter the clinical picture of the patient. These data reinforce the concept that the role of MCT8 is tissue-dependent: while neurons are highly dependent on MCT8, bone tissue, adipose tissue, muscle, and liver are less dependent on MCT8 and, therefore, may suffer the consequences of the exposition to high serum T3 levels.


Assuntos
Encefalopatias/genética , Transportadores de Ácidos Monocarboxílicos/genética , Mutação/genética , Síndrome da Resistência aos Hormônios Tireóideos/genética , Tri-Iodotironina/metabolismo , Sequência de Aminoácidos/genética , Encefalopatias/metabolismo , Criança , Humanos , Masculino , Hipertonia Muscular/genética , Hipotonia Muscular/genética , Simportadores , Síndrome da Resistência aos Hormônios Tireóideos/tratamento farmacológico , Tiroxina/uso terapêutico
18.
Rev. Assoc. Med. Bras. (1992, Impr.) ; 62(6): 594-601, Sept. 2016. tab, graf
Artigo em Inglês | LILACS | ID: biblio-829498

RESUMO

Summary The International Diabetes Federation (IDF-2015) estimates the existence of 30,900 children under 15 years old with type 1 diabetes mellitus (DM1) in Brazil, and an increase of 3.0% per year is expected. This review focused on meta-analysis and pediatric diabetes update articles in order to draw attention to the need of planning coping strategies to support this serious public health problem in coming years. DM1 is considered an immuno-mediated disease with a complex transmission influenced by genetic and environmental factors responsible for a gradual destruction of the insulin producing pancreatic beta cells. Seroconversion to DM1-associated autoantibodies and abnormalities in metabolic tests that assess insulin secretion and glucose tolerance can be used as predictive criteria of beta cells functional reserve and the onset of the clinical disease. Symptomatic DM1 treatment is complex and the maintenance of good metabolic control is still the only effective strategy for preserving beta cell function. Disease duration and hyperglycemia are both risk factors for the onset of chronic vascular complications that negatively affect the quality of life and survival of these patients. In this regard, health teams must be trained to provide the best possible information on pediatric diabetes, through continuing education programs focused on enabling these young people and their families to diabetes self-management.


Resumo A Federação Internacional de Diabetes (IDF-2015) estima a existência no Brasil de 30.900 menores de 15 anos portadores de diabetes mellitus tipo 1 (DM1), com previsão de aumento de 3,0% ao ano. Esta revisão buscou artigos de metanálise e atualização em diabetes infantil com o objetivo de alertar para a necessidade do planejamento de estratégias de enfrentamento deste que tende a ser um sério problema de saúde pública para os próximos anos. O DM1 é considerado uma doença imunomediada de transmissão complexa, influenciada por fatores genéticos e ambientais determinantes da destruição gradual das células beta pancreáticas produtoras de insulina. A positividade sorológica dos autoanticorpos associados ao DM1 e a alteração de testes metabólicos que avaliam a secreção de insulina e o estado glicêmico podem ser utilizados como critérios de previsão da reserva funcional de células beta e do início clínico da doença. O tratamento do DM1 sintomático é complexo, e a manutenção do bom controle metabólico é ainda a única estratégia efetiva de preservação das células beta ainda funcionantes. Tempo de duração da doença e hiperglicemia são fatores de risco para a instalação das complicações vasculares crônicas, que afetam negativamente a qualidade de vida e a sobrevida desses indivíduos. Torna-se necessária a formação de equipes de saúde preparadas para fornecer a melhor informação possível em diabetes infantil, através de programas de educação continuada, com potencial de capacitar esses jovens e suas famílias para o autocuidado.


Assuntos
Humanos , Pré-Escolar , Diabetes Mellitus Tipo 1/fisiopatologia , Brasil/epidemiologia , Fatores de Risco , Diabetes Mellitus Tipo 1/epidemiologia
19.
Arq Bras Endocrinol Metabol ; 54(9): 819-25, 2010 Dec.
Artigo em Português | MEDLINE | ID: mdl-21340175

RESUMO

OBJECTIVE: To report the main endocrine effects after cancer treatment in children and adolescents and associate them to the disease and its treatment. SUBJECTS AND METHODS: Clinical and lab evaluation for endocrinopathy was performed in 320 patients after cancer therapy have been followed for six years. RESULTS: The most prevalent endocrine late effects in patients were: 32 patients had short stature, nine of them were under growth hormone therapy. Precocious puberty was found in 14 patients, 10 of them received GnRH analog. Thyroid diseases were present in 19 patients (12 with hypothyroidism; six with thyroid nodules/cysts; one with chronic lymphocytic thyroidytis). Obesity was found in 18 patients. Six presented insipidus diabetes, five delayed puberty and three panhypopituitarism. Radiation was associated with the appearance of the aforementioned endocrinopathies. CONCLUSION: Ninety four of 320 (30%) patients presented endocrine late effects which emphasize the importance for these patients to be regularly followed-up in order to precociously diagnose endocrine late effects and provide them a better quality of life.


Assuntos
Antineoplásicos/efeitos adversos , Doenças do Sistema Endócrino/induzido quimicamente , Neoplasias/tratamento farmacológico , Adolescente , Criança , Doenças do Sistema Endócrino/epidemiologia , Métodos Epidemiológicos , Feminino , Humanos , Masculino , Neoplasias/classificação
20.
Arq Bras Endocrinol Metabol ; 53(6): 716-20, 2009 Aug.
Artigo em Português | MEDLINE | ID: mdl-19893913

RESUMO

OBJECTIVES: To describe the presence of prostatic tissue in 46,XX patients with the classical form of congenital adrenal hyperplasia (CAH); to evaluate the sensitivity and specificity of prostatic specific antigen (PSA) measured in congenital adrenal hyperplasia patients with regard to the detection of prostatic tissue in pelvic MRI. METHODS: We studied 52 children and adolescents, 32 with the classical form of congenital adrenal hyperplasia, 10 boys and 10 girls without CAH. Pelvic MRI was performed in all patients to detect prostatic tissue. Prostate specific antigen, testosterone and dihydrotestosterone were measured in all patients. We used Receiver Operating Characteristic Curve for PSA discrimination capacity. RESULTS: Five girls with congenital adrenal hyperplasia showed image of prostatic tissue on pelvic MRI. Prostate specific antigen showed sensitivity and specificity of 100% and 88.9%, respectively, taking 0.1 ng/mL as the cutoff level. CONCLUSIONS: The incidence of prostatic tissue in 46,XX patients with the classical form of congenital adrenal hyperplasia was 15.6%. PSA demonstrated to be a good marker of prostatic tissue in these patients and should be used to screen patients to be submitted to image studies.


Assuntos
Hiperplasia Suprarrenal Congênita/patologia , Di-Hidrotestosterona/sangue , Antígeno Prostático Específico/sangue , Próstata/patologia , Testosterona/sangue , Adolescente , Hiperplasia Suprarrenal Congênita/sangue , Hiperplasia Suprarrenal Congênita/genética , Biomarcadores Tumorais/sangue , Estudos de Casos e Controles , Criança , Feminino , Humanos , Cariotipagem , Imageamento por Ressonância Magnética , Masculino , Curva ROC , Sensibilidade e Especificidade , Processos de Determinação Sexual , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA